Safety of statins - Focus on clinical pharmacokinetics and drug interactions

被引:485
作者
Bellosta, S [1 ]
Paoletti, R [1 ]
Corsini, A [1 ]
机构
[1] Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy
关键词
drug interactions; fibrates; rhabdomyolysis; safety; statins;
D O I
10.1161/01.CIR.0000131519.15067.1f
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Statin monotherapy is generally well tolerated, with a low frequency of adverse events. The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of which occur infrequently. Because statins are prescribed on a long-term basis, however, possible interactions with other drugs deserve particular attention, as many patients will typically receive pharmacological therapy for concomitant conditions during the course of statin treatment. This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions.
引用
收藏
页码:50 / 57
页数:8
相关论文
共 65 条
[61]   In vitro and in vivo drug interactions involving human CYP3A [J].
Thummel, KE ;
Wilkinson, GR .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1998, 38 :389-430
[62]   EFFICACY AND LONG-TERM ADVERSE EFFECT PATTERN OF LOVASTATIN [J].
TOBERT, JA .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (15) :J28-J34
[63]   IN-VIVO INHIBITION PROFILE OF CYTOCHROME P450(TB) (CYP2C9) BY (+/-)-FLUVASTATIN [J].
TRANSON, C ;
LEEMANN, T ;
VOGT, N ;
DAYER, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) :412-417
[64]   HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein [J].
Wang, EJ ;
Casciano, CN ;
Clement, RP ;
Johnson, WW .
PHARMACEUTICAL RESEARCH, 2001, 18 (06) :800-806
[65]  
White CM, 2002, J CLIN PHARMACOL, V42, P963